Asthma is a common chronic disease affecting millions of individuals in the United States. Appropriate management and prevention of asthma symptoms is essential in order to maintain quality of life and reduce healthcare costs. Published consensus guidelines provide recommendations for asthma management and emphasize pharmacologic and nonpharmacologic components for long-term management. Major components of asthma management include environmental control measures, patient education and self-management, pharmacotherapy and periodic assessment. Since publication of the guidelines in 1997, there has been additional research and advances in our knowledge and understanding of asthma. Ongoing research focuses on issues such as regular versus as needed use of short-acting bronchodilators, early initiation of inhaled corticosteroids, safety of inhaled corticosteroids in children with asthma, combination therapy with inhaled corticosteroids and other long-term control agents, and reduction of inhaled corticosteroid doses. Advances in therapy and new knowledge about appropriate management strategies should be incorporated into clinical management strategies.
CDC. Asthma mortality and hospitalization among children and young adults—United States, 1980-1993. MMWR. 1996; 45(17): 350-353.
2.
CDC. Current trends asthma—United States, 1982-1992. MMWR. 1995; 43(51):952-955.
3.
Murphy SL. Deaths: Final Data for 1998. National Vital Statistics Reports; vol 48 no 11. Hyattsville, Maryland: National Center for Health Statistics. 2000.
4.
Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997; 156:787-793.
5.
National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Publication No. 97-4051. Bethesda, Maryland. 1997.
6.
Doerschung KC, Peterson MW, Dayton CS, et al. Asthma guidelines: an assessment of physician understanding and practice. Am J Respir Crit Care Med. 1999; 159:1735-1741.
7.
Busse WW, Calhoun WF, Sedgwick JD. Mechanism of airway inflammation in asthma. Am Rev Respir Dis. 1993; 147:S20-S24.
8.
Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis. 1990; 142:434-457.
9.
Bousquet J, Jeffery PK, Busse WW, et al. Asthma: from bronchoconstriction to air ways inflammation and remodeling. Am J Respir Crit Care Med. 2000; 161:1720-1745.
10.
Crapo RO. Pulmonary function testing. N Engl J Med. 1994; 331(1):25-30.
11.
Krieger JW, Song L, Takaro TK, et al. Asthma and the home environment of low-income urban children: preliminary findings from the Seattle-King county healthy home project. J Urban Health. 2000; 77(1):50-65.
12.
Carswell F, Birmingham K, Oliver J, et al. The respiratory effects of reduction of mite allergen in the bedrooms of asthmatic children—a double-blind controlled trial. Clin Exper Allergy. 1996; 26:386-396.
13.
Harding SM, Guzzo MR, Richter JE. The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms. Am J Respir Crit Care Med. 2000; 162:34-39.
14.
Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux?Chest. 1998; 114(1):275-283.
15.
Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med. 1996; 100(4):395-405.
16.
Kijander TO, Salomaa EM, Hietanen EK, et al. Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole. Chest. 1999; 116(5):1257-1264.
17.
Ignacio-Garcia JM, Gonzalez-Santos P.Asthma self-management education program by home monitoring of peak expiratory flow. Am J Respir Crit Care Med. 1995; 151(2):353-359.
18.
Lahdensuo A, Haahtela T, Herrla J, et al. Randomized comparison of guided self management and traditional treatment of asthma over one year. BMJ. 1996; 312(7033):748-752.
19.
Turner MO, Taylor D, Bennett R, et al. A randomized trial comparing peak expiratory flow and symptom self-management plans for patients with asthma attending a primary care clinic. Am J Respir Crit Care Med. 1998; 157:540-546.
20.
Suissa S, Ernst P, Boivin J, et al. A cohort analysis of excess mortality in asthma and the use of inhaled β2-agonists. Am J Respir Crit Care Med. 1994; 149:604-610.
21.
Spitzer WO, Suissa S, Ernst P, et al. The use of β2-agonists and the risk of death and near death from asthma. N Engl J Med. 1992; 326(8):501-506.
22.
Drazen JM, Israel E.Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med. 1996; 335(12):841-847.
23.
Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomized trial. Lancet. 2000; 35:1675-1679.
24.
Israel E, Drazen JM, Liggett SB. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000; 162(1):75-80.
25.
Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA. 2000; Sept 12; 97(19): 10483-10488.
26.
Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000; 343:332-336.
27.
Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994; 331(11):700-705.
28.
Selroos O, Pietinalho A, Lofroos AB, et al. Effect of early versus late intervention with inhaled corticosteroids in asthma. Chest. 1995; 108:1228-1234.
29.
Agertoft L, Pedersen S.Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Resp Med. 1994; 88:373-381.
30.
Dutiot JI, Salome CM, Woodcock AJ. Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not. Am Rev Respir Dis. 1987; 36:1174-1178.
31.
Simons FER. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med. 1997; 337: 1659-1665.
32.
Svendsen UG, Frolund L, Madsen F, et al. A comparison of the effects of sodium cromoglycate and beclomethasone dipropionate on pulmonary function and bronchial hyperreactivity in subjects with asthma. J Allergy Clin Immunol. 1987; 80:68-74.
33.
Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol. 2000; 105:1123-1129.
34.
Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med. 1999; 130:487-495.
35.
O’Byrne PM, Cuddy L, Taylor DM, et al. The clinical efficacy and cost benefit of inhaled corticosteroids as therapy in patients with mild asthma in primary care practice. Can Respir J. 1996; 3:169-175.
36.
Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000; 343(15):1054-1063.
37.
Weinberger M, Hendeles L.Theophylline in asthma. N Engl J Med. 1996; 334:1380-1388.
38.
Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998; 339:147-152.
39.
Hilman BC, Bairnsfather L, Washburne W, et al. Nebulized cromolyn sodium: safety, efficacy and role in the management of childhood asthma. Pediatr Allergy Immunol. 1987; 1:43-52.
40.
Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997; 126:177-183.
41.
Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics. 2000; 106(1):e8.
42.
Agertoft L, Pedersen S.Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000; 343(15):1064-1069.
43.
Wohl MEB, Majzoub JA. Asthma, steroids, and growth. N Engl J Med. 2000; 343:1113-1114
44.
Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med. 1997; 337(20):1412-1418.
45.
Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996; 153:1481-1488.
46.
van Noord JA, Schreurs AJM, Mol SJM, et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax. 1999; 54:207-212.
47.
Kelsen SG, Church NL, Gillman SA, et al. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J Asthma. 1999; 36(8):703-715.
48.
Bouros D, Bachlitzanakis N, Kottakis J, et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J. 1999; 14:627-632.
49.
Shrewsbury S, Pyke S, Britton M.Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000; 320:1368-1373.
50.
Verberne AAPH, Frost C, Duiverman EJ. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. Am J Respir Crit Care Med. 1998; 158:213-219.
51.
Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 1999; 160:1862-1868.
52.
Stempel DA. Montelukast added to inhaled beclomethasone in treatment of asthma (letter). Am J Respir Crit Care Med. 2000; 162:331.
53.
Virchow JC, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000; 162:578-585.
54.
Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol. 1999; 103:1075-1080.
55.
Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000; 106:1088-1095.
56.
Lofdahl CG, Reiss T, Leff JA, et al. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999; 319(7202):87-90.
57.
Nielsen LP, Pedersen B, Faurschou P, et al. Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics. Respir Med. 1999; 93:863-868.
58.
Milgrom H, Fick RB, Su JG, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med. 1999; 341:1966-1973.
59.
Borish L, Nelson H, Lanz MJ, et al. IL-4 receptor in moderate atopic asthma. A phase I/II randomized placebo-controlled trial. Am J Respir Crit Care Med. 1999; 160:1816-1823.
